Global Prostate Cancer Therapeutics Market to Exhibit a Remarkable CAGR of 8.1% during the Period 2016-2024

Published on : Apr 25, 2017

Albany, New York, April 25, 2017: Due to the increasing prevalence of prostate cancer, there are several new prostate cancer treatment research is going on in several areas at present. This has identified as a major driver for the growth of the therapeutic market for prostate cancer, finds a new report added to the wide repository of Market Research Hub (MRH). The title of the study is “Prostate Cancer Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024” which analyzes the current and future scenario of the global market. Additionally, a detailed qualitative analysis of drivers and restraints, opportunities and trends have been provided which gives buyer’s to access of the major aspects of the market.

At first, the therapeutics market report on prostate cancer comprises an elaborate executive summary, which includes market snapshot, considering 2015 as the base year. Researchers and doctors are always looking for more effective and alternative treatments for prostate cancer, such as the launch of promising emerging therapies, innovation in the development of new drugs and therapeutic biological products etc. As per the research estimations, the global prostate cancer therapeutics market to expand at a CAGR of 8.1% between 2016 and 2024. At this pace, the market will reach US$17.53 billion by the end of 2024.

Prostate Cancer is the most common cancer among men and is an abnormal and uncontrolled growth of cells in the prostate gland of a male individual. More specifically, it is the second type of cancer that is most deadly among U.S. men. According to National Cancer Institute, the maximum number of new cases of prostate cancer was 129.4 per 100,000 men per year. The number of deaths was 20.7 per 100,000 men per year. The findings state that, when prostate cancer is detected in its early stages, it can be effectively treated and cured. There are a number of ways to treat prostate cancer.

In the market overview section, the report provides statistics and data analysis of the country’s market with respect to the segments based on therapy type, distribution channels and regions. Regionally, the research throws lights on the major areas, such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Based on therapy type, the market has been segmented into:

  • Hormone therapy
  • Chemotherapy
  • Biologic therapy
  • targeted therapy

Click here to get more info with TOC in a PDF Format :

Hormonal therapies stop the growth of cancer cells by reducing the amount of testosterone in the body. Due to their effectiveness, hormonal therapies have an increased adoption among physicians. Moreover, on the basis of distribution channels, the global prostate cancer therapeutics market has been segmented into hospital pharmacy, retail pharmacy, online sales and others.

Moreover, competitive landscape of the market is also highlighted in the study, which has been analyzed on the major players leading in the market. Top players are Amgen, Inc., Pfizer, Inc., AstraZeneca, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc., Bayer AG, Ipsen Group, Johnson & Johnson (Janssen Biotech, Inc.), Sanofi, Endo Pharmaceuticals, Inc.

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top